REal World Data in LYmphoma and Survival in Adults (REALYSA)

Civil Hospices of Lyon

Status: Enrolling

Conditions: Burkitt Lymphoma (BL)); Marginal Zone Lymphoma (MZL); Hodgkin's Lymphoma (HL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Diffuse Large B Lymphoma (DLBCL); T-cell Lymphoma (T-NHL)

Treatments: Other: Real-life epidemiological platform of lymphoma in France

Study type: Observational

Funder types: Other

Identifiers

NCT03869619

2018-A01332-53 (Other Identifier)

69HCL18_0352

Details and patient eligibility

About

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.

REALYSA is a platform perfectly set up to

• Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)...
• Document treatment effectiveness in real life and observance
• Address socio-economical questions

Enrollment: 6,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signature of the consent form for participation in the REALYSA cohort
• Aged over 18 at the time of inclusion
• Diagnosed with lymphoma in the last 6 months (180 days)
• Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma

Exclusion criteria

• Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)

• Documented HIV infection

• Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:

  • Chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Hairy cell leukemia and variant
  • Lymphoplasmacytic lymphoma
  • Waldenström macroglobulinemia
  • Primary DLBCL of the central nervous system (CNS)
  • T-cell large granular lymphocytic leukemia
  • Chronic lymphoproliferative disorder of NK cells
  • Mycosis fungoides
  • Sézary syndrome
  • Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)
  • Post-transplant lymphoproliferative disorders (PTLD)

Trial design

6,000 participants in 1 patient group

All enrolled patients

Description:

All patient who signed the consent form for participation to the study

Treatment:

Other: Real-life epidemiological platform of lymphoma in France